PRIME-CKD

Less pills, better pills
Personalized Drug Response:
Implementation and Evaluation in CKD

Read more ›

About Prime-CKD

Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable. Currently there are no validated biomarkers (i.e. signal-substances that can be measured in blood or urine) in patients with CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice.

“Individual and optimal treatment for every kidney patient; that is what we aim for.”

What is our objective?

The researchproject PRIME-CKD (Personalized drug Response: IMplementation and Evaluation in Chronic Kidney Desease) has a unique advantage to address the challenge we are facing as it builds on recent discoveries of new biomarkers to help guide optimal treatment to individual patients. The research must lead to new therapies for the treatment of CKD.

Read more
Objective of Prime CKD

Latest News

PRIME-CKD is stepping up at World Kidney Day!

It cannot be emphasized enough: Chronic Kidney Disease (CKD) is a leading cause of death globally. The "one size fits all" approach to the treatment of CKD just isn't cutting it anymore. While new therapies exist, individual responses of patients vary considerably. That’s why PRIME-CKD is stepping up. We are moving ...
Read more

INCLIVA Valencia started with patient enrollment for CKD-bioMatch personalized medicine trial

The CKD-bioMatch trial is recruiting 125 patients with progressive CKD. Patients from Denmark, Germany, Spain, United Kingdom and Sweden are being included for the trial that will run for 3 years At INCLIVA, the Health Research Institute of Hospital Clínico Universitario de Valencia, recruitment has is progressing rapidly. Dr Jose Luis Górriz, Principal Investigator ...
Read more

PRIME-CKD publication: Using biomarkers to accelerate clinical trials – The regulatory evidence!

Traditionally, clinical outcomes that measure how a patient feels, functions, or survives are the preferred endpoints in clinical trials. However, in slowly developing diseases, such as chronic kidney disease (CKD), these endpoints may take a long time to manifest. Biomarkers can serve as so-called surrogate endpoints, acting as ...
Read more

Prime-CKD news in your mailbox

We can provide you with the latest information via RSS. Click the RSS icon if your browser supports RSS feeds (Chrome or addons).

Or use url https://www.prime-ckd.com/feed in a RSS-reader or an e-mail rss-feed.

Our partners

Copyright © 2024 - Webtail for UMCG Clinical Pharmacy and Pharmacology ]